Systemic Therapy for Recurrent, Metastatic, or Persistent Cervical Cancer

Guideline Objective

To update a previous guideline on chemotherapy options for women with recurrent, metastatic, or persistent cervical cancer.

The primary outcomes of interest are overall survival rate and quality of life. Other outcomes of interest include response rate, progression-free survival rate, and adverse effects. Second-line or higher therapy options are outside the scope of this guideline.

Patient Population

Women with metastatic, recurrent, or persistent cervical cancer for whom systemic therapy is indicated. This includes women with squamous cell carcinoma, adenosquamous carcinoma, or adenocarcinoma of the cervix.

Intended Guideline Users

Gynecologic oncologists or oncologists treating gynecologic cancers in the province of Ontario.

Research Question(s)

What are the systemic therapy options for women with recurrent, metastatic, or persistent cervical cancer?

The primary outcomes of interest are overall survival rate and quality of life. Other outcomes of interest include response rate, progression-free survival rate, and adverse effects.